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SUMMARY
Case-ascertained household transmission studies, in which households including an ‘index case ’
are recruited and followed up, are invaluable to understanding the epidemiology of influenza.
We used a simulation approach parameterized with data from household transmission studies to
evaluate alternative study designs. We compared studies that relied on self-reported illness in
household contacts vs. studies that used home visits to collect swab specimens for virological
confirmation of secondary infections, allowing for the trade-off between sample size vs. intensity
of follow-up given a fixed budget. For studies estimating the secondary attack proportion,
2–3 follow-up visits with specimens collected from all members regardless of illness were optimal.
However, for studies comparing secondary attack proportions between two or more groups,
such as controlled intervention studies, designs with reactive home visits following illness reports
in contacts were most powerful, while a design with one home visit optimally timed also
performed well.
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INTRODUCTION
Influenza virus is associated with a substantial global
burden of morbidity and mortality, yet many charac-
teristics of the disease are poorly understood including
transmissibility and its relationships with viral shed-
ding during infection, factors affecting infectiousness
and immunity, and the effectiveness of interventions
to reduce transmission. Households are important in
influenza epidemiology [1], and it has been estimated
that around a third of all influenza transmission oc-
curs in households [2]. Historically, household studies
have provided invaluable insights into influenza
epidemiology [3], while recent household studies have
investigated the effectiveness of antiviral treatment
and prophylaxis [4–8], hand hygiene [9–11], face
masks [10–13], transmissibility of seasonal influenza
[14] and 2009 pandemic influenza A(H1N1) [15–22].
There are two main types of design for household
studies.A cohort of initially uninfected households can
be recruited and then followed up through periods
of influenza activity [3, 23]. While this is regarded
as the gold standard for influenza household studies,
this design can be extremely resource-intensive be-
cause the expected number of households in which
an infection occurs is relatively small. Alternatively,
households can be enrolled in a study once influenza
infection is identified in one member (an ‘ index’ case),
and followed up to observe secondary infections. The
latter design is termed a case-ascertained design [24],
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and is the focus of this paper. Case-ascertained studies
are believed to be themost efficientmethod of assessing
secondary transmission of influenza because smaller
sample sizes are required to observe an equivalent
number of secondary infections compared to a cohort
study. In case-ascertained studies, influenza trans-
mission is typically measured via the secondary attack
proportion (SAP), defined as the proportion of house-
hold contacts that are infected with influenza virus
from the index case [15].
While some case-ascertained studies rely entirely on
self-reports of symptoms and signs associated with
acute respiratory illnesses [12–17], repeated home
visits can be arranged to collect specimens and allow
virological confirmation of influenza virus infections
[10, 11, 19–22]. Since secondary cases shed detectable
virus for 3–5 days after illness onset it is important
to consider the number and timing of visits in order to
maximize the number of secondary cases that can be
confirmed virologically. However, home visits can be
associated with significant costs and there is a resource
trade-off between the number of home visits per
household vs. the total number of households that can
be recruited given a fixed total budget for fieldwork.
Selecting an appropriate study design is part of
Good Clinical Practice and use of suboptimal designs
could squander research funding and put participants
at unnecessary risk and inconvenience. In this paper
we evaluate which study designs make the most cost-
effective use of resources for accurately and robustly
estimating the SAP in a transmission study, and for
maximizing statistical power in a comparative study.
METHODS
As a basic scenario, we considered case-ascertained
studies of household transmission of influenza virus
where index cases are recruited after presentation at
a study clinic. In this scenario, relatively inexpensive
point-of-care rapid tests which are able to detect in-
fluenza virus infection with moderate sensitivity and
high specificity [25] are used to identify index cases
with influenza. For those index cases with a positive
rapid test result, an initial home visit is conducted as
soon as possible to collect laboratory specimens from
all household contacts to determine whether there are
any co-primary cases. If a co-primary case is found,
the family are not enrolled in the study [10, 26].
A series of additional home visits might be conducted
at later dates to collect further specimens for viro-
logical confirmation of secondary cases. Symptom
diaries can also be provided to household members to
permit self-reporting of signs and symptoms associ-
ated with acute respiratory illness (ARI). We define
ARI as the presence of two of the following symptoms:
fever (o37.8 xC), cough, headache, sore throat, or
myalgia, and influenza-like illness (ILI) as temperature
(o37.8 xC) plus cough or sore throat [10, 21]. ILI is
a more specific but less sensitive indicator of acute
influenza virus infection than ARI [10, 21, 27].
Transmission study
In a transmission study primary interest is in estimat-
ing the household SAP. If home visits are not feasible
logistically, studies based on self-reported secondary
cases can be conducted [14, 15]. However, no clinical
definition of influenza has high sensitivity and high
specificity and therefore estimates of SAP based on
clinical definitions may not accurately or robustly
measure the true SAP [10, 21, 27]. If feasible, home
visits are an important component of a design allow-
ing virological confirmation of secondary cases. It is
also possible to restrict home visits to households
where contacts report illness [5–7]. Since sample size
calculations without any home visits are straight-
forward using standard methods, here we focus
on comparing transmission studies with one or more
follow-up visits vs. the use of ILI or ARI in contacts
to trigger home visits, or clinical outcome definitions
alone.
Comparative study
In a typical comparative study, one or more active
intervention is compared with a control. In these
studies primary interest is usually in comparing the
effectiveness of interventions on household SAPs with
measures such as the incidence rate ratio, relative risk,
or odds ratio, and studies are designed that allow
moderate to high power for detection of intervention
effects. In this scenario virological confirmation of
secondary cases might be less important since inter-
vention effects might still be identifiable in compari-
sons of clinical outcomes between arms. We compare
two-arm comparative studies with no follow-up visits,
visits triggered by ARI or ILI, or one or more follow-
up visits regardless of illness.
Data sources
To permit simulation of alternative study designs,
some basic parameters are required which characterize
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influenza transmission in households (Table 1). We
assumed that in addition to the index case there are
three additional household members. We assumed
that an index case is seen in a clinic and a subsequent
home visit confirms that the remaining household
members are negative within 24 h of symptom onset
of the index case. We also assumed that there is no
within-household tertiary transmission because ter-
tiary transmission is relatively rare and should have
little effect on the estimation of SAP.
Costs are also required, since an optimal design
must trade-off the total sample size with the number
of follow-up visits. We specified the recruitment and
enrolment costs per household as CE and the cost of a
home visit as CV. In a previous study in Hong Kong,
CE was three times as much as CV (Table 1). In sen-
sitivity analyses we also considered ratios of 2:1 and
4:1. With a fixed fieldwork budget of C, the total
number of households n that can be recruited depends
on the number of follow-up home visits v and can be
calculated with the formula n=C/(CE+vCV).
Statistical analysis
We re-analysed data on viral shedding during illness
associated with natural influenza virus infection
[10, 28]. The probability of virological confirmation
by RT–PCR was estimated using logistic regression
with a cubic spline term for time since illness onset.
For transmission studies, accurately estimating the
SAP is of primary importance. Consequently, as a
design with only one home visit will miss more infec-
tions than those with more home visits, studies with
more home visits are less biased than those with fewer
home visits. However, this should come at the cost of
greater variance in parameter estimates due to the
reduced sample size. Therefore the choice of more
home visits relative to decreased overall sample size
should represent a bias-variance trade-off. We exam-
ined the overall efficiency of estimation by estimating
the mean squared error (MSE) and mean absolute
error (MAE) of the SAP under each design. The MSE
and MAE are both measures of the expected differ-
ence between the estimate of a parameter and the
actual parameter value, and a smaller MSE or MAE
indicates greater precision and less bias.
For comparative studies, we estimated the power of
each potential design to detect a specific treatment
effect in terms of a reduction in the estimated SAP in
the intervention vs. the control group, expressed as an
odds ratio. To calculate power, a logistic generalized
estimating equation [29] accounting for within-family
correlations was fitted to the simulated data. The stat-
istical power was estimated as the number of simu-
lated datasets in which the intervention effect was
identified at a significance level of Pf0.05.
Due to the nonlinearities in transmission dynamics
we used a simulation approach to compare alternative
study design variants [30]. For each study design
variant we used a Monte Carlo approach to simulate
a set of 2500 datasets. The MSE and MAE or power
of each variant were evaluated by statistical analysis
of the set of 2500 simulated datasets and compared
across design variants. Further technical details are
provided in the Supplementary Appendix (available
online).
Table 1. Epidemiological parameters
Parameter Value Source
Serial interval for influenza Weibull distribution
with mean 3.2 days
[21]
SAP control group 10% Assumed
SAP intervention group 5%, 7.5% Assumed
Total number of people per household 4 Assumed
Specificity of RT–PCR 100% Assumed
Sensitivity of ARI compared to virologically confirmed infection 68% [10]
Specificity of ARI compared to virologically confirmed infection 86% [10]
Sensitivity of ILI compared to virologically confirmed infection 40% [10]
Specificity of ILI compared to virologically confirmed infection 98% [10]
Cost of recruiting an index case US$ 360 (B. J. Cowling, personal
communication)
Cost of a home visit US$ 120 (B. J. Cowling, personal
communication)
SAP, Secondary attack proportion; ARI, acute respiratory illness ; ILI, influenza-like illness.
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Sensitivity analyses
In addition to examining the sensitivity of our results
to costs as described above, we also examined how a
shorter serial interval of mean 2.6 days [15, 31, 32] or
a longer serial interval of mean 3.6 days [33] would
affect our results.
RESULTS
We parameterized our simulation model using results
from the literature and analyses of data from a house-
hold study (Table 1) [10, 28]. In a secondary analysis
of data from a field study, we estimated that the prob-
ability of virological confirmation of infection was
highest when specimens were collected within 1–3 days
of illness onset (Fig. 1).
Transmission studies
We examined the optimal timing of home visits for
a transmission study with one or with two home
visits. We found that the optimal timing was 6 days
from ARI onset in the index case for a one home-
visit design, 5 and 7 days from ARI onset in the index
case for a two-home-visit design and 3, 5, and 7 days
for a three-home-visit design. We found that as the
study budget increased, designs with two and
then three home visits led to the lowest MSE and
MAE, and this was robust to differences in the CE:CV
ratio (Fig. 2). As total study budget increases,
designs with four, five, and even more home visits will
become optimal in terms of reducing the MSE (data
not shown). We also found that studies with more
home visits performed substantially better in terms
of MSE and MAE than those using only self-reported
clinical outcomes of ILI and ARI. Using ILI to trig-
ger home visits appeared to be as accurate as con-
ducting home visits for all families regardless of
illness.
Comparative studies
For a comparative study we found that the optimal
visit timing was 6 days from ARI onset in the index
case for a one-home-visit design, 5 and 7 days from
ARI onset in the index case for a two-home-visit
design (Fig. 3) and 3, 5, and 7 days for a three-home-
visit design. For the comparative study, a design
in which a home visit occurs after being triggered
by ARI in a family member was most powerful.
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Fig. 1. (a) Intensity of viral shedding associated with influenza A virus infections, and (b) probability of virological con-
firmation of influenza A virus infection in a subject by day of collection of a nose and throat swab. (Based on data from Lau
et al. [28].)
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In designs where visits were conducted to swab all
participants regardless of illness, a design with one
home visit on day 6 was most powerful to detect an
overall difference in SAP between the control and
intervention groups (Fig. 4). However, differences
in power between designs with one home visit and
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Fig. 3. Power of comparative study designs with alternative home visit schedules by days since acute respiratory illness onset
in the index case for (a) studies with one home visit and (b) studies with two home visits.
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Fig. 2. (a) Estimated mean squared error (MSE) and (b) mean absolute error (MAE) of the secondary attack proportion for
varying transmission studies. For a given budget, lower values of MSE and MAE indicate better designs. The black lines
represent study designs involving home visits with subsequent virological confirmation for all families on the specified days,
the medium grey lines represent self-report of influenza-like illness (ILI) or acute respiratory illness (ARI) without virological
confirmation, and the light grey lines represent a home visit with subsequent virological confirmation when an ARI or ILI is
reported within a family.
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multiple home visits were very small, particularly as
the cost of home visits decreased relative to the cost of
enrolment. Designs with home visits outperformed
those relying solely on the self-reported clinical out-
comes of ARI and ILI. Finally, studies based on ILI
outcome had higher power than those based on ARI.
Sensitivity analyses
Using a serial interval with mean 2.6 or 3.6 days re-
sulted in the optimal timing of visits being shifted
slightly earlier or later, respectively, but the patterns
in terms of the optimal strategy for visits remained
similar. For example, for a comparative design the
optimal timing with a serial interval with mean 2.6
days was day 5 for one visit and days 4 and 6 after
illness onset for two visits, while for a serial interval
with mean 3.6 days it was 6 days for one visit and 5
and 7 days after illness onset for two visits.
DISCUSSION
Careful consideration is necessary when planning
case-ascertained studies of influenza transmission.
If the aim of a study is to assess the household
SAP, then conducting more than one home visit in
most circumstances would be optimal (Fig. 2). In
the case of a study comparing SAPs between two or
more groups, such as a controlled trial, the optimal
design would be to have one home visit on day 6.
However, the differences in power between designs
with one visit or multiple visits were relatively small
(Fig. 4). Our results would suggest that given a
reasonable cost per home visit, the use of home visits
is a cost-effective strategy compared to relying solely
on clinical diagnosis of influenza from self-report
data. When resources for home visits are limited, ARI
or preferably ILI could be used to trigger home visits
(Fig. 3) and this method performs well. In com-
parative studies based on clinical outcomes alone, ILI
was associated with greater power than ARI because
of the very high specificity of ILI case definition.
Despite the number of clinical and epidemiological
studies using longitudinal (repeated-measure) designs,
there is a paucity of literature discussing the optimal
choice of the number of repeated measurements [34].
The majority of work considering the design of ran-
domized controlled trials with repeated measurements
treats the number of repeated measurements as a
fixed and known aspect of design [35, 36]. Of the few
studies which have treated the number of repeated
measurements as a variable to be optimized, Winkens
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Fig. 4. Power of alternative designs for comparative studies with respect to (a) an odds ratio of 0.67 (true relative risk of 0.7)
and (b) an odds ratio 0.84 (true relative risk of 0.85). The black lines represent home visits with subsequent virological
confirmation for all families on the specified days, the medium grey lines represent self-report of influenza-like illness (ILI) or
acute respiratory illness (ARI) without virological confirmation and the light grey lines represent a home visit with sub-
sequent virological confirmation triggered by reports of ARI or ILI by a household contact.
Design of influenza transmission studies 111
et al. [37] consider the optimal number of repeated
measurements when treatment outcomes are linearly
divergent while Cook et al. [38] consider the optimal
choice of measurements in epidemic processes. Those
approaches are not directly applicable to the scenarios
described in the present study because the probability
of influenza infection and subsequent detection is
highly nonlinear with regard to time since infection
(Fig. 1). While our work is specific to household trans-
mission of influenza virus, the results may generally
translate to similar studies of other respiratory viruses
such as rhinovirus and respiratory syncytial virus,
provided that corrections are made for their specific
natural history [39].
Throughout all simulations the use of ARI or ILI
to trigger home visits performed as well or better than
the use of home visits for all families. One caveat
is that in that scenario some illnesses might not be
reported leading to missed infections, while symptom
diaries might be completed more meticulously if
household members knew that home visits would be
conducted regardless of illness. One other possibility
is to invite participants to swab themselves during
follow-up, thereby reducing the cost of a home visit
but maintaining a virological outcome. We did not
include self-swabbing in our analyses as we could not
find any data on the sensitivity of self-swabbing
compared to swabs collected by experts.
The optimal timing of home visits depends on the
serial interval, which determines when infected sec-
ondary cases will on average have illness onset, and
also depends on the probability of virological confir-
mation of infection by day since illness onset. In a
novel analysis of secondary data we showed that the
probability of virological confirmation of an infection
is highest if swabs are taken on days 1–3 of illness (Fig.
1). While we compared study designs in terms of time
since index case illness onset, in some protocols timing
is specified as time from enrolment of a family and if
enrolment is completed on average 24 h or 48 h after
symptom onset, then 1 or 2 days should be subtracted
to calculate optimal timing of visits after enrolment.
Figure 3 shows that home-visit timings of around
4–7 days after symptom onset work reasonably well.
While the optimal timing may seem late compared
to the mean serial interval, it should be noted that
later follow-up visits allow the detection of secondary
cases with earlier infection (who are still shedding de-
tectable virus) as well as those with later infection.
Our study has practical limitations when consider-
ing its application to the planning of future studies.
First, our results on the optimal timing of visits de-
pend on estimates of the serial interval and the dur-
ation of detectable viral shedding. We have focused
on studies of influenza A epidemiology. Studies in-
cluding influenza B should consider how differences in
viral shedding [28, 40] and other epidemiological
characteristics might affect these conclusions. Second,
future improvements in the cost or accuracy of lab-
oratory methods could change the optimal number of
home visits. Third, we would caution that although it
appears diagnosis of influenza based on self-report
provides less power than influenza detection through
home visits and subsequent RT–PCR, clinical influ-
enza may be the only feasible outcome measure in
some settings, and an important primary outcome in
studies such as antiviral prophylaxis if the aim were
to reduce illness in household contacts rather than
prevent infection. We incorporated alternative as-
sumptions about the relative costs of enrolment and
follow-up, but other logistical considerations may
play a role in study design. For example, if only one
clinic is available for recruitment then a study with
many home visits and a smaller sample size might be
preferred, but the reverse could be true if community
nurses capable of conducting home visits were in short
supply. If paired sera were available from baseline
(pre-infection) and convalescence (21–28 days after
infection), comparison of antibody titres could pro-
vide serological confirmation of infection, although
it can be challenging to obtain sera from participants
in community studies. Finally, Yang et al. [24] noted
that in simulation studies direct randomization of
family members rather than cluster randomization
of families would be more powerful. However, this is
not always possible, for example in studies where non-
pharmaceutical interventions or antiviral treatments
are given to the index case to attempt to reduce on-
wards transmission.
Despite these potential limitations, our results
should serve as useful guidelines for researchers plan-
ning future case-ascertained studies of influenza trans-
mission and control. Our findings illustrate that if
feasible, collection of specimens for virological testing
can be a cost-effective use of resources.
NOTE
Supplementary material accompanies this paper on
the Journal’s website (http://journals.cambridge.org/
hyg).
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